IRIS Accounts Production v25.1.4.42 04314936 director 1.1.24 31.12.24 31.12.24 18.9.25 false true false false true false Auditors Opinion Ordinary 1.00000 B Ordinary 1.00000 C Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh043149362023-12-31043149362024-12-31043149362024-01-012024-12-31043149362022-12-31043149362023-01-012023-12-31043149362023-12-3104314936ns15:EnglandWales2024-01-012024-12-3104314936ns14:PoundSterling2024-01-012024-12-3104314936ns10:Director12024-01-012024-12-3104314936ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3104314936ns10:SmallEntities2024-01-012024-12-3104314936ns10:Audited2024-01-012024-12-3104314936ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3104314936ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3104314936ns10:FullAccounts2024-01-012024-12-3104314936ns10:OrdinaryShareClass12024-01-012024-12-3104314936ns10:OrdinaryShareClass22024-01-012024-12-3104314936ns10:OrdinaryShareClass32024-01-012024-12-3104314936ns10:CompanySecretary12024-01-012024-12-3104314936ns10:RegisteredOffice2024-01-012024-12-3104314936ns5:CurrentFinancialInstruments2024-12-3104314936ns5:CurrentFinancialInstruments2023-12-3104314936ns5:ShareCapital2024-12-3104314936ns5:ShareCapital2023-12-3104314936ns5:SharePremium2024-12-3104314936ns5:SharePremium2023-12-3104314936ns5:RetainedEarningsAccumulatedLosses2024-12-3104314936ns5:RetainedEarningsAccumulatedLosses2023-12-3104314936ns5:LandBuildingsns5:ShortLeaseholdAssets2024-01-012024-12-3104314936ns5:FurnitureFittings2024-01-012024-12-3104314936ns5:ComputerEquipment2024-01-012024-12-3104314936ns5:LandBuildingsns5:ShortLeaseholdAssets2023-12-3104314936ns5:FurnitureFittings2023-12-3104314936ns5:ComputerEquipment2023-12-3104314936ns5:LandBuildingsns5:ShortLeaseholdAssets2024-12-3104314936ns5:FurnitureFittings2024-12-3104314936ns5:ComputerEquipment2024-12-3104314936ns5:LandBuildingsns5:ShortLeaseholdAssets2023-12-3104314936ns5:FurnitureFittings2023-12-3104314936ns5:ComputerEquipment2023-12-3104314936ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3104314936ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3104314936ns10:OrdinaryShareClass12024-12-3104314936ns10:OrdinaryShareClass22024-12-3104314936ns10:OrdinaryShareClass32024-12-31
REGISTERED NUMBER: 04314936 (England and Wales)















AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

FOR

GENIAL GENETIC SOLUTIONS LIMITED

GENIAL GENETIC SOLUTIONS LIMITED (REGISTERED NUMBER: 04314936)






CONTENTS OF THE FINANCIAL STATEMENTS
for the Year Ended 31 December 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


GENIAL GENETIC SOLUTIONS LIMITED

COMPANY INFORMATION
for the Year Ended 31 December 2024







DIRECTOR: Mr J Bender





SECRETARY: Mr J A Evans





REGISTERED OFFICE: Unit 62 Coworkz Business Centre
Minerva Avenue, Off Sovereign Way
Chester
Flintshire
CH1 4QL





REGISTERED NUMBER: 04314936 (England and Wales)





AUDITORS: Kings CAP Ltd
Statutory Auditor
4 Grovelands
Boundary Way
Hemel Hempstead
Hertfordshire
HP2 7TE

GENIAL GENETIC SOLUTIONS LIMITED (REGISTERED NUMBER: 04314936)

BALANCE SHEET
31 December 2024

31.12.24 31.12.23
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 28,825 19,338

CURRENT ASSETS
Stocks 5 18,966 -
Debtors 6 1,056,641 1,248,010
Cash at bank 117,916 201,753
1,193,523 1,449,763
CREDITORS
Amounts falling due within one year 7 1,024,245 1,349,189
NET CURRENT ASSETS 169,278 100,574
TOTAL ASSETS LESS CURRENT
LIABILITIES

198,103

119,912

CAPITAL AND RESERVES
Called up share capital 8 1,497 1,497
Share premium 23,519 23,519
Retained earnings 173,087 94,896
SHAREHOLDERS' FUNDS 198,103 119,912

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 16 September 2025 and were signed by:





Mr J Bender - Director


GENIAL GENETIC SOLUTIONS LIMITED (REGISTERED NUMBER: 04314936)

NOTES TO THE FINANCIAL STATEMENTS
for the Year Ended 31 December 2024

1. STATUTORY INFORMATION

Genial Genetic Solutions Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The company's going concern status is dependent upon the continued financial support of the parent undertaking. Having made appropriate enquiries at the time of approving these accounts the director considers that the company and the parent undertaking have adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis in preparing these accounts.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Short leasehold - 20% on cost
Fixtures and fittings - 15% on cost
Computer equipment - 25% on cost

Stocks
Work in progress is valued at the lower of cost and net realisable value.

Cost is calculated using the first-in, first-out method and includes all purchase, transport, and handling costs in bringing stocks to their present location and condition.

GENIAL GENETIC SOLUTIONS LIMITED (REGISTERED NUMBER: 04314936)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued

Financial instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities
Basic financial liabilities, including creditors and loans from fellow group undertakings, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

GENIAL GENETIC SOLUTIONS LIMITED (REGISTERED NUMBER: 04314936)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 31 December 2024

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 12 (2023 - 17 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
Short and Computer
leasehold fittings equipment Totals
£    £    £    £   
COST
At 1 January 2024 11,520 26,231 80,209 117,960
Additions - - 20,994 20,994
Disposals - (24,462 ) (66,954 ) (91,416 )
At 31 December 2024 11,520 1,769 34,249 47,538
DEPRECIATION
At 1 January 2024 5,718 26,231 66,673 98,622
Charge for year 1,161 266 7,164 8,591
Eliminated on disposal - (25,401 ) (63,099 ) (88,500 )
At 31 December 2024 6,879 1,096 10,738 18,713
NET BOOK VALUE
At 31 December 2024 4,641 673 23,511 28,825
At 31 December 2023 5,802 - 13,536 19,338

5. STOCKS
31.12.24 31.12.23
£    £   
Work-in-progress 18,966 -

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.24 31.12.23
£    £   
Trade debtors 132,537 386,685
Amounts owed by group undertakings 850,000 750,000
Other debtors 19,003 7,579
Tax 37,847 84,851
Prepayments 17,254 18,895
1,056,641 1,248,010

GENIAL GENETIC SOLUTIONS LIMITED (REGISTERED NUMBER: 04314936)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 31 December 2024

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.24 31.12.23
£    £   
Trade creditors 961 8,557
Amounts owed to group undertakings 204,536 413,458
Social security and other taxes 5,017 -
Value added tax 1,796 27,873
Other creditors 6,107 20,020
Accruals and deferred income 771,328 800,751
Accruals 34,500 78,530
1,024,245 1,349,189

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.12.24 31.12.23
value: £    £   
1,000 Ordinary £1 1,000 1,000
3 B Ordinary £1 3 3
494 C Ordinary £1 494 494
1,497 1,497

9. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Sara Brown (Senior Statutory Auditor)
for and on behalf of Kings CAP Ltd

10. FRC ETHICAL STANDARD - PROVISIONS AVAILABLE FOR SMALL ENTITIES

In common with many other businesses of our size and nature we use our auditors to prepare and submit returns to the tax authorities and assist with the preparation of the financial statements.

11. ULTIMATE CONTROLLING PARTY

The company's immediate parent undertaking is K2 Medical Systems Holdings Limited a company incorporated in England & Wales.

The ultimate controlling party is Constellation Software Inc. The ultimate controlling party address is 66 Wellington Street West, Suite 5300, TD Bank Tower, Toronto, Ontaria, M5K 1E6. The company is registered in Canada.